Thrombotic risk factors in chinese budd-chiari syndrome patients: An observational study with a systematic review of the literature

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 878-884

  Qi, Xingshun ^a   Wu, Feifei ^a   Ren, Weirong ^a   He, Chuangye ^a   Yin, Zhanxin ^a   Niu, Jing ^a   Bai, Ming ^a   Yang, Zhiping ^a   Wu, Kaichun ^a,b   Fan, Daiming ^a,b   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Budd chiari syndrome; Factor v leiden mutation; Myeloproliferative neoplasm; Paroxysmal nocturnal haemoglobinuria; Prothrombin g20210a mutation

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; JANUS KINASE 2;

ADULT; ARTICLE; BUDD CHIARI SYNDROME; CYANOCOBALAMIN DEFICIENCY; FEMALE; FOLIC ACID DEFICIENCY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTHEMIA; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIGENS, CD55; ANTIGENS, CD59; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BUDD-CHIARI SYNDROME; CHI-SQUARE DISTRIBUTION; CHINA; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERHOMOCYSTEINEMIA; JANUS KINASE 2; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTHROMBIN; RISK FACTORS;

EID: 84877026539     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0784     Document Type: Article

References (50)

1. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764
2. Valla DC. Primary Budd-Chiari syndrome. J Hepatol 2009; 50: 195-203
3. De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010; 5: 487-494
4. Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis 2011; 43: 503-514
5. Riva N, Donadini MP, Dentali F, et al. Clinical approach to splanchnic vein thrombosis: Risk factors and treatment. Thromb Res 2012; 130 (Suppl 1): S1-S3
6. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364-2368
7. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591
8. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175
9. Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48: 264-268
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148
11. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061
12. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals- Hatem D, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-4929
13. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-5623
14. Qi X, Yang Z, Bai M, et al. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011; 33: 1087-1103
15. Qi X, Zhang C, Han G, et al. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: A prospective study. J Gastroenterol Hepatol 2012; 27: 1036-1043
16. Lin GL, Xu PQ, Qi H, et al. Relations of Budd-Chiari syndrome to prothrombin gene mutation. Hepatobiliary Pancreat Dis Int 2004; 3: 214-218
17. Wang ZG, Zhang FJ, Yi MQ, et al. Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients. ANZ J Surg 2005; 75: 55-63
18. Xu PQ, Ma XX, Ye XX, et al. Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20-year experience. Hepatobiliary Pancreat Dis Int 2004; 3: 391-394
19. Gao Y, Chen S, Yu C. Applicability of different endovascular methods for treatment of refractory Budd-Chiari syndrome. Cell Biochem Biophys 2011; 61: 453-460
20. Meng QY, Sun NF, Wang JX, et al. Endovascular treatment of Budd-Chiari syndrome. Chin Med J (Engl) 2011; 124: 3289-3292
21. Qi X, He C, Han G, et al. Prevalence of paroxysmal nocturnal hemoglobinuria in Chinese patients with Budd-Chiari syndrome or portal vein thrombosis. J Gastroenterol Hepatol 2013; 28: 148-152
22. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951
23. Fermo I, Vigano' D'Angelo S, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753
24. Lin JS, Shen MC, Tsai W, et al. The prevalence of C677T mutation in the methylenetetrahydrofolate reductase gene and its association with venous thrombophilia in Taiwanese Chinese. Thromb Res 2000; 97: 89-94
25. Young C, Horton R. Putting clinical trials into context. Lancet 2005; 366: 107-108
26. Clarke M. Doing new research? Don't forget the old. PLoS Med 2004; 1: e35
27. Feng B, Xu K, Jiang H, et al. Relationship between factor V Leiden mutation and Chinese Budd-Chiari syndrome and its clincal significance. Zhonghua Yi Xue Za Zhi (Article in Chinese) 2000; 80: 354-357
28. Feng B, Xu K, Jin C, et al. Study on relationship between Chinese Budd-Chiari syndrome and factor V Leiden mutation. Zhongguo Yi Ke Da Xue Xue Bao (Article in Chinese) 2001; 30: 53-55
29. Zhao G, Gu J, Zhang Y, et al. Bai cha zhong he zhong huan ze ning xue mei ji yin G20210A bian yi guan xi yan jiu. Jiangsu Lin Chuang Yi Xue Za Zhi (Abstract and article in Chinese) 2002; 6: 125-129
30. Li XM, Wei YF, Hao HL, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002; 71: 11-14
31. Wang S, Wei Y, Li J. The relationship between fibrinogen gene-455G/A polymorphisms and Budd-Chiari syndrome. Zhonghua Nei Ke Za Zhi (Article in Chinese) 2004; 43: 753-755
32. Guo C, Bian J, Wang Y, et al. Effects of multiple elements in drinking water on inferior vena cava membranous obstruction type of the Budd-Chiari syndrome in Heze area of Shandong Province. Zhongguo Di Fang Bing Xue Za Zhi (Article in Chinese) 2005; 24: 207-209
33. Zheng H, Lian J, Qi H, et al. FV Leiden and FII G20210A mutations in patients with Budd-Chiari syndrome. Zhengzhou Da Xue Xue Bao 2005; 40: 456-458
34. He Y, Zheng H, Lian J, et al. Budd-chiari zhong he zheng huan zhe ning xue yin zi XIII Val34Leu ji yin duo tai xing de jian ce. Zhonghua Xue Ye Xue Za Zhi (Abstract and article in Chinese) 2005; 26: 564-565
35. Lin G, Xu P, Qi H, et al. A study on the correlations between pathogenesis of Budd-Chiari syndrome and Factor V Leiden and Factor II G20210A mutations. Zhonghua Pu Tong Wai Ke Za Zhi (Article in Chinese) 2006; 21: 275-277
36. Lian J, He Y, Yu H, et al. Distribution of eNOS gene 4a/b VNTR polymorphism in Budd-Chiari syndrome patients in Han population of Henan province. Zhengzhou Da Xue Xue Bao (Article in Chinese) 2007; 42: 422-424
37. Yu C, Gao Y, Geng X, et al. The research on the mutation of coagulation factor V of diseased tissues in Budd-Chiari syndrome. Lin Chuang Wai Ke Za Zhi (Article in Chinese) 2007; 15: 743-745
38. Han X, Chen C, Duan G, et al. Budd-Chiari zhong he zheng yu kang lin zhi kang ti zhong he zheng de xiang guan xing yan jiu. Shandong Yi Yao 2008; 48: 109-110
39. Wang J, Lu Z, Sun G, et al. Bu jia shi zhong he zheng xiang guan wei xian yin su yan jiu. Zhongguo Yi Xue Chuang Xin (Abstract and article in Chinese) 2010; 7: 42-44
40. Zhang B, Wang L, Liu X, et al. Relation of iodine level of drinking water and coagulation in patients with membrane obstruction of inferior vena cava in Budd- Chiari syndrome. Huan Jing Yu Jian Kang Za Zhi (Article in Chinese) 2011; 28: 44-46
41. Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997; 87: 377-385
42. Lu Y, Zhao Y, Liu G, et al. Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb Res 2002; 106: 7-12
43. Yanqing H, Fangping C, Qinzhi X, et al. No association between thrombosis and factor V gene polymorphisms in Chinese Han population. Thromb Haemost 2003; 89: 446-451
44. Hoekstra J, Leebeek FW, Plessier A, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 2009; 51: 696-706
45. Garcia-Pagan JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-815
46. Bosy-Westphal A, Ruschmeyer M, Czech N, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003; 77: 1269-1277
47. Mangia A, Margaglione M, Cascavilla I, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999; 94: 2983-2987
48. Hoekstra J, Casellas-Caro M, Garcia-Pagán JC, et al. Etiologic factors underlying Budd-Chiari syndrome and portal vein thrombosis: The role of site-specific thrombosis. Hepatology 2010; 52: 896A.
49. Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome - A systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol 2013; 28: 432-442
50. Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011; 124: e365-e368.